Your browser is no longer supported. Please, upgrade your browser.
Aethlon Medical, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own0.80% Shs Outstand12.09M Perf Week-16.67%
Market Cap28.09M Forward P/E- EPS next Y-1.02 Insider Trans-20.81% Shs Float11.81M Perf Month-9.09%
Income-7.40M PEG- EPS next Q-0.20 Inst Own5.30% Short Float5.19% Perf Quarter41.94%
Sales0.80M P/S35.12 EPS this Y63.60% Inst Trans-47.28% Short Ratio0.28 Perf Half Y45.70%
Book/sh0.96 P/B2.29 EPS next Y-44.30% ROA-54.30% Target Price- Perf Year-26.67%
Cash/sh0.95 P/C2.32 EPS next 5Y- ROE-59.30% 52W Range1.18 - 3.73 Perf YTD-10.93%
Dividend- P/FCF- EPS past 5Y36.60% ROI-67.80% 52W High-41.02% Beta0.63
Dividend %- Quick Ratio10.00 Sales past 5Y-3.10% Gross Margin- 52W Low86.44% ATR0.24
Employees8 Current Ratio10.00 Sales Q/Q50.00% Oper. Margin- RSI (14)38.43 Volatility8.16% 10.87%
OptionableNo Debt/Eq0.00 EPS Q/Q28.80% Profit Margin- Rel Volume0.12 Prev Close2.32
ShortableYes LT Debt/Eq0.00 EarningsFeb 10 AMC Payout- Avg Volume2.17M Price2.20
Recom2.00 SMA20-14.15% SMA50-10.64% SMA20019.98% Volume274,815 Change-5.17%
Feb-11-21 06:10AM  
Feb-10-21 02:30PM  
Feb-07-21 01:06AM  
Feb-04-21 08:02AM  
Jan-29-21 04:32AM  
Jan-06-21 08:02AM  
Jan-04-21 08:02AM  
Dec-16-20 08:02AM  
Nov-03-20 08:01AM  
Oct-29-20 11:45AM  
Oct-28-20 04:15PM  
Oct-19-20 08:01AM  
Oct-13-20 10:30AM  
Sep-09-20 08:01AM  
Aug-27-20 08:01AM  
Aug-11-20 04:15PM  
Aug-06-20 12:43AM  
Jun-25-20 04:15PM  
Jun-22-20 08:31AM  
Jun-18-20 12:49PM  
Jun-16-20 08:30AM  
Mar-24-20 08:58AM  
Mar-06-20 12:08PM  
Feb-25-20 03:25PM  
Feb-24-20 10:22AM  
Feb-17-20 01:37PM  
Feb-13-20 05:35AM  
Feb-10-20 04:15PM  
Feb-06-20 08:01AM  
Jan-23-20 01:02PM  
Jan-22-20 02:28PM  
Jan-21-20 02:40PM  
Jan-17-20 08:49AM  
Dec-17-19 04:18PM  
Dec-13-19 07:00AM  
Nov-15-19 05:04AM  
Nov-01-19 04:15PM  
Oct-29-19 03:17PM  
Oct-28-19 07:00AM  
Oct-14-19 03:55PM  
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah ChetanDirectorDec 17Sale2.1126,85256,58016,641Dec 18 05:00 PM